phrykt

Rocket Pharmaceuticals, Inc. (RCKT): who owns it and who trades it

As of Nov 16, 2026, RCKT insiders reported 27 open-market sales worth $1M and 1 purchase worth $34.4K in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Martin Wilson (General Counsel), with $462K. 6 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Rocket Pharmaceuticals

From the latest filings

Overall: more selling than buying. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns RCKT

179 funds and institutions reported RCKT shares worth $344M at the end of Q2 2026, about 92% of the company. The largest holder is Rtw Investments, LP with 16.2%.

Funds and institutions (13F) 92%Everyone else 8%

10 largest owners, by share of the company

Rtw Investments, LP16.2%
BlackRock, Inc.9.1%
Vanguard Portfolio Management LLC5.3%
Citigroup Inc4.5%
Marshall Wace, LLP3.7%
Millennium Management LLC3.7%
Newtyn Management, LLC3.7%
Maverick Capital Ltd3.6%
Vanguard Capital Management LLC3.5%
AQR Capital Management LLC3.1%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Rtw Investments, LP17.69M16.20%$60.5MNo change
BlackRock, Inc.9.92M9.09%$33.9M+27%
Vanguard Portfolio Management LLC5.81M5.32%$19.9M+24%
Citigroup Inc4.87M4.46%$16.6M-5%
Marshall Wace, LLP4.03M3.69%$13.8M+33%
Millennium Management LLC4.00M3.66%$13.7M+28%
Newtyn Management, LLC4.00M3.66%$13.7M+26%
Maverick Capital Ltd3.92M3.59%$13.4M+10%
Vanguard Capital Management LLC3.78M3.47%$12.9M+0%
AQR Capital Management LLC3.39M3.10%$11.6M+10%
Goldman Sachs Group Inc2.83M2.59%$9.7M+65%
Monaco Asset Management SAM2.48M2.27%$8.5M+21%
Geode Capital Management, LLC2.37M2.17%$8.1M+8%
Federated Hermes, Inc.2.30M2.11%$7.9M+125%
JPMorgan Chase & Co1.99M1.82%$6.7M–
Jacobs Levy Equity Management, Inc1.97M1.81%$6.8M+374%
State Street Corp1.82M1.67%$6.2M-59%
Dimensional Fund Advisors LP1.13M1.03%$3.8M+290%
Morgan Stanley1.06M0.97%$3.6M-47%
Opaleye Management Inc.1.00M0.92%$3.4M+5%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, RCKT insiders reported $34.4K of open-market purchases and $1M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$34.4K
1 trades, 1 people
Sales, 12 months
$1M
27 trades, 6 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Nov 9, 2026
Filed Nov 12, 2026

Purchases and sales by month

$275K$275KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 9, 2026Sarbani ChaudhuriSee RemarksSale4,872$2.33$11.3KForm 4
Nov 5, 2026Martin WilsonGeneral CounselSale53,389$2.39$128KForm 4
Sep 11, 2026Martin WilsonGeneral CounselSale75,364$3.40$256KForm 4
Aug 18, 2026Martin WilsonGeneral CounselSale631$3.38$2.1KForm 4
Aug 18, 2026Gaurav ShahCEOSale2,293$3.38$7.8KForm 4
Aug 13, 2026Gaurav ShahCEOSale2,837$3.38$9.6KForm 4
Aug 13, 2026Martin WilsonGeneral CounselSale3,493$3.38$11.8KForm 4
Aug 11, 2026Christopher James StevensChief Operating OfficerSale36,658$3.50$128KForm 4
Aug 11, 2026Sarbani ChaudhuriSee RemarksSale4,701$3.50$16.5KForm 4
May 21, 2026Gaurav ShahCEOSale55,684$3.09$172KForm 4
May 19, 2026Gaurav ShahCEOSale2,409$3.01$7.3KForm 4
May 19, 2026Martin WilsonGeneral CounselSale662$3.01$2KForm 4
May 19, 2026John MilitelloSee RemarksSale384$3.01$1.2KForm 4
May 13, 2026Martin WilsonGeneral CounselSale3,361$3.61$12.1KForm 4
May 13, 2026Gaurav ShahCEOSale2,728$3.61$9.8KForm 4
May 13, 2026John MilitelloSee RemarksSale855$3.61$3.1KForm 4
May 7, 2026Sarbani ChaudhuriSee RemarksSale17,650$3.84$67.8KForm 4
Feb 18, 2026John MilitelloSee RemarksSale1,157$3.34$3.9KForm 4
Feb 18, 2026Gaurav ShahCEOSale5,990$3.34$20KForm 4
Feb 18, 2026Martin WilsonGeneral CounselSale1,376$3.34$4.6KForm 4
Feb 13, 2026Martin WilsonGeneral CounselSale12,253$3.31$40.6KForm 4
Feb 13, 2026John MilitelloSee RemarksSale3,726$3.31$12.3KForm 4
Feb 13, 2026Gaurav ShahCEOSale12,279$3.31$40.6KForm 4
Jan 2, 2026Elisabeth BjorkDirectorPurchase10,000$3.44$34.4KForm 4
Nov 18, 2025John MilitelloSee RemarksSale1,086$2.98$3.2KForm 4
Nov 18, 2025Jonathan David SchwartzSee RemarksSale2,545$2.98$7.6KForm 4
Nov 18, 2025Gaurav ShahCEOSale6,276$2.98$18.7KForm 4
Nov 18, 2025Martin WilsonGeneral CounselSale1,646$2.98$4.9KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Martin WilsonGeneral Counsel–$462KNov 5, 2026
Gaurav ShahCEO, Director–$286KAug 18, 2026
Christopher James StevensChief Operating Officer–$128KAug 11, 2026
Sarbani ChaudhuriSee Remarks–$95.6KNov 9, 2026
Elisabeth BjorkDirector$34.4K–Jan 2, 2026
John MilitelloSee Remarks–$23.7KMay 19, 2026
Jonathan David SchwartzSee Remarks–$7.6KNov 18, 2025
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

RCKT short interest

High short interest. 14.8% of RCKT shares are sold short: about 1 share in 7. Over the last 12 reports the number of shares short went down 22%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 16.24M RCKT shares were sold short, 14.8% of the shares outstanding, down 0.2% from the report before. At the average daily volume of 1.79M shares, buying them all back would take about 9.1 trading days (days to cover).

Shares short, % of all shares

14.8%May 15Oct 3021.7%

Days to cover

9.1May 15Oct 3012.9

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202616.24M14.80%-0%1.79M9.1
Oct 15, 202616.28M14.83%+8%2.44M6.7
Sep 30, 202615.05M13.71%+1%2.17M6.9
Sep 15, 202614.85M13.53%+1%1.34M11.1
Aug 31, 202614.71M13.40%+2%1.50M9.8
Aug 14, 202614.39M13.11%-7%1.68M8.6
Jul 31, 202615.50M14.12%-6%1.30M11.9
Jul 15, 202616.57M15.18%-9%2.44M6.8
Jun 30, 202618.16M16.63%-17%3.65M5.0
Jun 15, 202621.90M20.06%-2%2.62M8.3
May 29, 202622.45M20.56%+7%2.36M9.5
May 15, 202620.95M19.19%-3%2.08M10.1

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Rocket Pharmaceuticals company events

Rocket Pharmaceuticals filed 13 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Oct 6, 2026.

  1. Oct 6, 2026AgreementRocket Pharmaceuticals, Inc., together with its subsidiaries Spacecraft Seven, LLC and Zebrafish Merger Sub II, LLC (together with the Company, “Borrower”), entered into a Loan and Security Agreement with the several banks and other financial institutions or entities from time to time party thereto… Filing
  2. Sep 15, 2026AnnouncementShared information with investors. Filing
  3. Aug 27, 2026LeadershipThe Board of Directors of Rocket Pharmaceuticals, Inc. adopted the Rocket Pharmaceuticals, Inc. Severance and Change in Control Program. Filing
  4. Aug 10, 2026ResultsReleased financial results. Filing
  5. Aug 3, 2026AnnouncementShared information with investors. Filing
  6. Jun 30, 2026LeadershipDeparture of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers. Filing
  7. Jun 12, 2026DealRocket Pharmaceuticals, Inc. completed the previously disclosed sale of its Rare Pediatric Disease Priority Review Voucher to a large pharmaceutical company. Filing
  8. May 21, 2026VoteReported shareholder vote results. Filing
  9. May 7, 2026ResultsReleased financial results. Filing
  10. Apr 28, 2026AgreementRocket Pharmaceuticals, Inc. entered into a definitive asset purchase agreement pursuant to which the Company has agreed to sell a Rare Pediatric Disease Priority Review Voucher. Filing
  11. Mar 27, 2026AnnouncementShared information with investors. Filing
  12. Mar 10, 2026AgreementRocket Pharmaceuticals, Inc. entered into a sales agreement with Cantor Fitzgerald & Co., with respect to an at-the-market offering program pursuant to which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.01 per share, having an… Filing
  13. Feb 26, 2026ResultsReleased financial results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Rocket Pharmaceuticals financials

Famous investors that hold RCKT

6 of the 50 well-known investors we track reported holding RCKT in their latest 13F filing. The largest position is Israel Englander's, worth $12.7M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 20264.82M$12.7M0.0%+21%
Lee Ainslie · Maverick CapitalQ3 20263.84M$10.1M0.1%-2%
Jim Simons · Renaissance TechnologiesQ3 2026928,731$2.4M0.0%+17%
Steve Cohen · Point72 Asset ManagementQ3 2026516,662$1.4M0.0%-23%
Ken Griffin · Citadel AdvisorsQ3 2026365,695$962K0.0%+414%
Paul Tudor Jones · Tudor Investment CorpQ3 202650,493$133K0.0%No change

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named RCKT in the last 120 days.

FiledHolderFormStake
Oct 30, 2026Vanguard Portfolio Management13G/A1.3%
Oct 30, 2026Vanguard Portfolio Management13G/A1.3%

Questions about Rocket Pharmaceuticals, Inc. (RCKT) stock

Who owns the most RCKT stock?

The largest reported owner of Rocket Pharmaceuticals, Inc. (RCKT) is Rtw Investments, LP, with 16.2% of the company. In total, 179 funds and institutions reported holding RCKT at the end of Q2 2026, together about 92% of the shares. See the largest owners.

Are RCKT insiders buying or selling?

In the last 12 months, RCKT insiders reported 1 open-market purchase worth $34.4K and 27 sales worth $1M. The latest trade was on Nov 9, 2026. See every trade.

What is the short interest in RCKT?

As of Oct 30, 2026, 16.24M RCKT shares were sold short, 14.8% of the shares outstanding, down 0.2% from the report before. At the average daily volume of 1.79M shares, buying them all back would take about 9.1 trading days (days to cover). See the history.

Which famous investors hold RCKT?

6 of the 50 well-known investors we track reported RCKT in their latest 13F filing, including Israel Englander, Lee Ainslie, Jim Simons. The largest position is worth $12.7M. See all holders.

Executive pay

Rocket Pharmaceuticals's chief executive was paid a total of $3.5M for the year ended Dec 31, 2025, down 49% from $6.8M the year before. In the last 12 months, Rocket Pharmaceuticals's executives and directors bought $34.4K of stock on the open market and sold $1M.

Chief executive, total pay$3.5MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Other top executives, average$3.5MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.